{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:49:40Z","timestamp":1761130180211,"version":"3.38.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203139\/Z\/16\/Z"],"award-info":[{"award-number":["203139\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203139\/A\/16\/Z"],"award-info":[{"award-number":["203139\/A\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013468\/1"],"award-info":[{"award-number":["MR\/N013468\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Oxford Health Biomedical Research Centre"},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"publisher","award":["AARF-21-846366"],"award-info":[{"award-number":["AARF-21-846366"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>With promising disease-modifying therapies (DMTs) emerging and good evidence to support risk reduction in the delay of dementia onset and progression, it is important to understand the profile of patients attending memory assessment services to estimate what proportion of patients might benefit from different types of interventions. The Oxford Brain Health Clinic (OBHC) is a psychiatry-led, clinical-research service that offers memory clinic patients detailed clinical assessments and equal access to research opportunities as part of their secondary care pathway. In this work, we describe the characteristics of OBHC patients in terms of demographics, diagnoses and prevalence of potentially modifiable risk factors compared with a cohort of healthy volunteers and the average memory clinic population. Our results suggest that high research consent rates (91.5%) in the OBHC resulted in a highly representative cohort of the clinical population. Based on Lecanemab trial inclusion criteria, 24.6% of the OBHC population may be suitable for further investigation into DMTs. Furthermore, 67.4% of OBHC patients have at least one potentially modifiable risk factor that may benefit from lifestyle interventions, particularly those focused on depression, sleep and physical activity.<\/jats:p>","DOI":"10.1038\/s41598-025-91178-7","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T17:29:02Z","timestamp":1741195742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of dementia risk factors in the Oxford Brain Health Clinic"],"prefix":"10.1038","volume":"15","author":[{"given":"J.","family":"Blane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Griffanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Pretorius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Shabir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Maffei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fossey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Raymont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Martos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. E.","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"91178_CR1","unstructured":"Alzheimer\u2019s Research UK. Tipping point: the future of dementia. (2023)."},{"key":"91178_CR2","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","volume":"101","author":"RR Pittock","year":"2023","unstructured":"Pittock, R. R. et al. Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. Neurology 101, e1837\u2013e1849. https:\/\/doi.org\/10.1212\/WNL.0000000000207770 (2023).","journal-title":"Neurology"},{"key":"91178_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston, G. et al. Dementia prevention, intervention, and care: 2024 report of the lancet standing commission. Lancet 404, 572\u2013628. https:\/\/doi.org\/10.1016\/S0140-6736(24)01296-0 (2024).","journal-title":"Lancet"},{"key":"91178_CR4","unstructured":"Long, S., Benoist, C., Weidner, W. World Alzheimer Report 2023: Reducing dementia risk: Never too early, never too late. (London, England, 2023)."},{"key":"91178_CR5","unstructured":"Royal College of Psychiatrists. National Audit of Dementia Spotlight Audit in Memory Assessment Services national report. (Healthcare Quality Improvement Partnership, London, 2023\/24)."},{"key":"91178_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/jad-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier, W. M. & Scheltens, P. Amsterdam dementia cohort: Performing research to optimize care. J. Alzheimers Dis. 62, 1091\u20131111. https:\/\/doi.org\/10.3233\/jad-170850 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"91178_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jalz.2012.09.012","volume":"9","author":"M Kivipelto","year":"2013","unstructured":"Kivipelto, M. et al. The finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER): Study design and progress. Alzheimer\u2019s Dement. 9, 657\u2013665. https:\/\/doi.org\/10.1016\/j.jalz.2012.09.012 (2013).","journal-title":"Alzheimer\u2019s Dement."},{"key":"91178_CR8","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu, T. et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385, 2255\u20132263. https:\/\/doi.org\/10.1016\/S0140-6736(15)60461-5 (2015).","journal-title":"Lancet"},{"key":"91178_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100576","author":"GB Frisoni","year":"2023","unstructured":"Frisoni, G. B. et al. Dementia prevention in memory clinics: Recommendations from the European task force for brain health services. Lancet Reg. Health Eur. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100576 (2023).","journal-title":"Lancet Reg. Health Eur."},{"key":"91178_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067808","volume":"13","author":"MC O'Donoghue","year":"2023","unstructured":"O\u2019Donoghue, M. C. et al. Oxford brain health clinic: Protocol and research database. BMJ Open 13, e067808. https:\/\/doi.org\/10.1136\/bmjopen-2022-067808 (2023).","journal-title":"BMJ Open"},{"key":"91178_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings, J. et al. Lecanemab: Appropriate use recommendations. J. Prev. Alzheimers Dis. 10, 362\u2013377. https:\/\/doi.org\/10.14283\/jpad.2023.30 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"91178_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000351671","volume":"36","author":"S Hsieh","year":"2013","unstructured":"Hsieh, S., Schubert, S., Hoon, C., Mioshi, E. & Hodges, J. R. Validation of the Addenbrooke\u2019s cognitive examination III in frontotemporal dementia and Alzheimer\u2019s disease. Dement. Geriatr. Cogn. Disord. 36, 242\u2013250. https:\/\/doi.org\/10.1159\/000351671 (2013).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"91178_CR13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11606-009-0928-6","volume":"24","author":"PC Smith","year":"2009","unstructured":"Smith, P. C., Schmidt, S. M., Allensworth-Davies, D. & Saitz, R. Primary care validation of a single-question alcohol screening test. J. Gen. Intern. Med. 24, 783\u2013788. https:\/\/doi.org\/10.1007\/s11606-009-0928-6 (2009).","journal-title":"J. Gen. Intern. Med."},{"key":"91178_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke, K., Spitzer, R. L. & Williams, J. B. The PHQ-9: Validity of a brief depression severity measure. J. Gen. Intern. Med. 16, 606\u2013613. https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x (2001).","journal-title":"J. Gen. Intern. Med."},{"key":"91178_CR15","unstructured":"Milton, K., Engeli, A., Townsend, T., Coombes, E., Jones, A. The selection of a project level measure of physical activity. (Sport England, London, 2017)."},{"key":"91178_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12955-020-01626-3","volume":"18","author":"L Batchelder","year":"2020","unstructured":"Batchelder, L. et al. Rasch analysis of the long-term conditions questionnaire (LTCQ) and development of a short-form (LTCQ-8). Health Qual. Life Outcomes 18, 375. https:\/\/doi.org\/10.1186\/s12955-020-01626-3 (2020).","journal-title":"Health Qual. Life Outcomes"},{"key":"91178_CR17","doi-asserted-by":"crossref","unstructured":"Devlin, N., Pickard, S. & Busschbach, J. in Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide 1\u201312 (Springer International Publishing, 2022).","DOI":"10.1007\/978-3-030-89289-0_1"},{"key":"91178_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/ageing\/25.2.113","volume":"25","author":"RS Bucks","year":"1996","unstructured":"Bucks, R. S., Ashworth, D. L., Wilcock, G. K. & Siegfried, K. Assessment of activities of daily living in dementia: development of the Bristol activities of daily living scale. Age Ageing 25, 113\u2013120. https:\/\/doi.org\/10.1093\/ageing\/25.2.113 (1996).","journal-title":"Age Ageing"},{"key":"91178_CR19","doi-asserted-by":"publisher","first-page":"103273","DOI":"10.1016\/j.nicl.2022.103273","volume":"36","author":"L Griffanti","year":"2022","unstructured":"Griffanti, L. et al. Adapting UK Biobank imaging for use in a routine memory clinic setting: The Oxford Brain Health Clinic. NeuroImage Clin. 36, 103273. https:\/\/doi.org\/10.1016\/j.nicl.2022.103273 (2022).","journal-title":"NeuroImage Clin."},{"key":"91178_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/s0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston, G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet commission. Lancet 396, 413\u2013446. https:\/\/doi.org\/10.1016\/s0140-6736(20)30367-6 (2020).","journal-title":"Lancet"},{"key":"91178_CR21","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1017\/s104161021700268x","volume":"30","author":"JA Mat\u00edas-Guiu","year":"2018","unstructured":"Mat\u00edas-Guiu, J. A. et al. Conversion between Addenbrooke\u2019s cognitive examination iii and mini-mental state examination. Int. Psychogeriatr. 30, 1227\u20131233. https:\/\/doi.org\/10.1017\/s104161021700268x (2018).","journal-title":"Int. Psychogeriatr."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91178-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91178-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91178-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T17:29:08Z","timestamp":1741195748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91178-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91178"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91178-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CEM is a cofounder and shareholder of Exprodo Software, which was used to develop the BHC database. CEM served on a Biogen Brain Health Consortium (unpaid). All the other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7765"}}